1 |
Biological: benralizumab, biological: placebo to mepolizumab |
Benralizumab |
[2] D04923 D04923, D09874 D09874 💬 |
IL5 [2] IL5, IL5RA 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
044 [1] 44 💬 |
2 |
Biological: mepolizumab, biological: placebo to benralizumab |
Benralizumab |
[2] D04923 D04923, D09874 D09874 💬 |
IL5 [2] IL5, IL5RA 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
044 [1] 44 💬 |
3 |
Mepolizumab |
Mepolizumab |
[1] D04923 D04923 💬 |
IL5 [1] IL5 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
044 [4] 44, 45, 98, 162 💬 |
4 |
Mepolizumab (a-il-5 antibody) |
Mepolizumab |
[1] D04923 D04923 💬 |
IL5 [1] IL5 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
162 [1] 162 💬 |
5 |
Mepolizumab 100 mg |
Mepolizumab |
[1] D04923 D04923 💬 |
IL5 [1] IL5 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
098 [1] 98 💬 |
6 |
Mepolizumab 300 mg |
Mepolizumab |
[1] D04923 D04923 💬 |
IL5 [1] IL5 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
098 [1] 98 💬 |
7 |
Nucala |
- |
- |
- |
- |
044 [2] 44, 45 💬 |
8 |
Nucala 100 mg powder for solution for injection |
- |
- |
- |
- |
044 [2] 44, 45 💬 |
9 |
Sb-240563 (mepolizumab) |
Mepolizumab |
[1] D04923 D04923 💬 |
IL5 [1] IL5 💬 |
Allograft rejection [13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
044 [2] 44, 45 💬 |